Key Drivers
- Gross margin
- Strong cash flow
- Expense drag
AIAI Summary
NBIX should increasingly be viewed as an emerging multi-asset growth platform rather than a pure INGREZZA story, but the stock's upside now depends on CRENESSITY and Soleno proving they can diversify revenue fast enough to offset concentration and valuation risk if INGREZZA growth cools.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin
- •Strong cash flow
- •Expense drag
NBIX pairs exceptional gross margins, solid profitability, strong free cash flow, and a sturdy balance sheet, but heavy spending, share-based compensation, and a premium valuation constrain upside.
Price Behavior
Key Price Behavior Insights:
- •Breakout trend
- •Overbought momentum
- •Support test
NBIX has surged on a breakout-driven uptrend over the last month, but the move is now stretched with overbought momentum and a slight pullback, so holding $155.80–$150.59 is key while $161.32 remains the breakout hurdle.
Broke out from the $128–$133 range and then eased slightly after the recent high, signaling possible consolidation
Sentiment & News
Key News Insights:
- •Strong Sales
- •Pipeline Expansion
- •Clinical Support
Neurocrine delivered strong Q1 sales and earnings, reaffirmed INGREZZA guidance, and expanded its growth pipeline through Soleno, new CRENESSITY data, and fresh obesity/schizophrenia studies.
Overall, the news reinforces Neurocrine's near-term commercial strength and supports a constructive long-term growth outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings